Free Trial

Rodman & Renshaw's Rating of Telomir Pharmaceuticals on 2/21/2025

On February 21, 2025, Rodman & Renshaw updated its outlook on Telomir Pharmaceuticals (NASDAQ:TELO) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Rodman & Renshaw

DateCompanyAction
3/19/2025
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
Initiated Coverage
1/28/2025
Talphera, Inc. stock logo
TLPH
Talphera
Initiated Coverage
1/28/2025
PolyPid Ltd. stock logo
PYPD
PolyPid
Initiated Coverage
1/28/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Initiated Coverage
1/28/2025
Indivior PLC stock logo
INDV
Indivior
Initiated Coverage
1/28/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
Initiated Coverage
More Ratings From Rodman & Renshaw